FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129534492> ?p ?o ?g. }

• W2129534492 endingPage "356" @default.
• W2129534492 startingPage "349" @default.
• W2129534492 abstract "REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide. We tested the hypothesis that near complete inhibition of factor IXa with pegnivacogin during percutaneous coronary intervention, followed by partial reversal with anivamersen, would reduce ischaemic events compared with bivalirudin, without increasing bleeding.We did a randomised, open-label, active-controlled, multicentre, superiority trial to compare REG1 with bivalirudin at 225 hospitals in North America and Europe. We planned to randomly allocate 13,200 patients undergoing percutaneous coronary intervention in a 1:1 ratio to either REG1 (pegnivacogin 1 mg/kg bolus [>99% factor IXa inhibition] followed by 80% reversal with anivamersen after percutaneous coronary intervention) or bivalirudin. Exclusion criteria included ST segment elevation myocardial infarction within 48 h. The primary efficacy endpoint was the composite of all-cause death, myocardial infarction, stroke, and unplanned target lesion revascularisation by day 3 after randomisation. The principal safety endpoint was major bleeding. Analysis was by intention to treat. This trial is registered at ClinicalTrials.gov, identifier NCT01848106. The trial was terminated early after enrolment of 3232 patients due to severe allergic reactions.1616 patients were allocated REG1 and 1616 were assigned bivalirudin, of whom 1605 and 1601 patients, respectively, received the assigned treatment. Severe allergic reactions were reported in ten (1%) of 1605 patients receiving REG1 versus one (<1%) of 1601 patients treated with bivalirudin. The composite primary endpoint did not differ between groups, with 108 (7%) of 1616 patients assigned REG1 and 103 (6%) of 1616 allocated bivalirudin reporting a primary endpoint event (odds ratio [OR] 1·05, 95% CI 0·80-1·39; p=0·72). Major bleeding was similar between treatment groups (seven [<1%] of 1605 receiving REG1 vs two [<1%] of 1601 treated with bivalirudin; OR 3·49, 95% CI 0·73-16·82; p=0·10), but major or minor bleeding was increased with REG1 (104 [6%] vs 65 [4%]; 1·64, 1·19-2·25; p=0·002).The reversible factor IXa inhibitor REG1, as currently formulated, is associated with severe allergic reactions. Although statistical power was limited because of early termination, there was no evidence that REG1 reduced ischaemic events or bleeding compared with bivalirudin.Regado Biosciences Inc." @default.
• W2129534492 created "2016-06-24" @default.
• W2129534492 creator A5003831287 @default.
• W2129534492 creator A5004345373 @default.
• W2129534492 creator A5004956623 @default.
• W2129534492 creator A5005158159 @default.
• W2129534492 creator A5007480001 @default.
• W2129534492 creator A5010922693 @default.
• W2129534492 creator A5011091435 @default.
• W2129534492 creator A5011361567 @default.
• W2129534492 creator A5012922168 @default.
• W2129534492 creator A5016139987 @default.
• W2129534492 creator A5016604632 @default.
• W2129534492 creator A5017098029 @default.
• W2129534492 creator A5018212759 @default.
• W2129534492 creator A5024045722 @default.
• W2129534492 creator A5024193392 @default.
• W2129534492 creator A5025786528 @default.
• W2129534492 creator A5028142480 @default.
• W2129534492 creator A5029909593 @default.
• W2129534492 creator A5032028897 @default.
• W2129534492 creator A5033831989 @default.
• W2129534492 creator A5037527199 @default.
• W2129534492 creator A5038384001 @default.
• W2129534492 creator A5039528291 @default.
• W2129534492 creator A5043046383 @default.
• W2129534492 creator A5047980929 @default.
• W2129534492 creator A5067237537 @default.
• W2129534492 creator A5067347864 @default.
• W2129534492 creator A5071106457 @default.
• W2129534492 creator A5077862111 @default.
• W2129534492 creator A5086196151 @default.
• W2129534492 creator A5086692319 @default.
• W2129534492 creator A5087955593 @default.
• W2129534492 creator A5089865834 @default.
• W2129534492 date "2016-01-01" @default.
• W2129534492 modified "2023-10-01" @default.
• W2129534492 title "Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial" @default.
• W2129534492 cites W133624405 @default.
• W2129534492 cites W1535768967 @default.
• W2129534492 cites W1551289483 @default.
• W2129534492 cites W1918944513 @default.
• W2129534492 cites W1967833179 @default.
• W2129534492 cites W1980585134 @default.
• W2129534492 cites W1999840444 @default.
• W2129534492 cites W2009281456 @default.
• W2129534492 cites W2016664086 @default.
• W2129534492 cites W2028126801 @default.
• W2129534492 cites W2046794276 @default.
• W2129534492 cites W2055085177 @default.
• W2129534492 cites W2058915460 @default.
• W2129534492 cites W2066074720 @default.
• W2129534492 cites W2069100517 @default.
• W2129534492 cites W2079175326 @default.
• W2129534492 cites W2079532743 @default.
• W2129534492 cites W2100181290 @default.
• W2129534492 cites W2103311193 @default.
• W2129534492 cites W2111237091 @default.
• W2129534492 cites W2122779695 @default.
• W2129534492 cites W2147270034 @default.
• W2129534492 cites W2149933092 @default.
• W2129534492 cites W2151442275 @default.
• W2129534492 cites W2154736824 @default.
• W2129534492 cites W2155363644 @default.
• W2129534492 cites W4292856638 @default.
• W2129534492 doi "https://doi.org/10.1016/s0140-6736(15)00515-2" @default.
• W2129534492 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26547100" @default.
• W2129534492 hasPublicationYear "2016" @default.
• W2129534492 type Work @default.
• W2129534492 sameAs 2129534492 @default.
• W2129534492 citedByCount "100" @default.
• W2129534492 countsByYear W21295344922016 @default.
• W2129534492 countsByYear W21295344922017 @default.
• W2129534492 countsByYear W21295344922018 @default.
• W2129534492 countsByYear W21295344922019 @default.
• W2129534492 countsByYear W21295344922020 @default.
• W2129534492 countsByYear W21295344922021 @default.
• W2129534492 countsByYear W21295344922022 @default.
• W2129534492 countsByYear W21295344922023 @default.
• W2129534492 crossrefType "journal-article" @default.
• W2129534492 hasAuthorship W2129534492A5003831287 @default.
• W2129534492 hasAuthorship W2129534492A5004345373 @default.
• W2129534492 hasAuthorship W2129534492A5004956623 @default.
• W2129534492 hasAuthorship W2129534492A5005158159 @default.
• W2129534492 hasAuthorship W2129534492A5007480001 @default.
• W2129534492 hasAuthorship W2129534492A5010922693 @default.
• W2129534492 hasAuthorship W2129534492A5011091435 @default.
• W2129534492 hasAuthorship W2129534492A5011361567 @default.
• W2129534492 hasAuthorship W2129534492A5012922168 @default.
• W2129534492 hasAuthorship W2129534492A5016139987 @default.
• W2129534492 hasAuthorship W2129534492A5016604632 @default.
• W2129534492 hasAuthorship W2129534492A5017098029 @default.
• W2129534492 hasAuthorship W2129534492A5018212759 @default.
• W2129534492 hasAuthorship W2129534492A5024045722 @default.
• W2129534492 hasAuthorship W2129534492A5024193392 @default.
• W2129534492 hasAuthorship W2129534492A5025786528 @default.
• W2129534492 hasAuthorship W2129534492A5028142480 @default.
• W2129534492 hasAuthorship W2129534492A5029909593 @default.

• next